Acelyrin, Inc.(SLRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLRN Acelyrin, Inc.

Market Closed 03-21 16:00:00 EDT

2.75

-0.02

-0.72%

盘后2.80

+0.05+1.82%

17:07 EDT

High2.84	Low2.70	Vol1.39M
Open2.74	D1 Closing2.77	Amplitude4.91%
Mkt Cap276.93M	Tradable Cap199.63M	Total Shares100.70M
T/O3.85M	T/O Rate1.92%	Tradable Shares72.59M
P/B0.60	ROE-44.54%	EPS-2.68
52wk High7.86	52wk Low1.85	P/E-1.03
Dividend0.00	Div.Yield0.00	ROA-30.89%

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"SLRN","market":"US","secType":"STK","nameCN":"Acelyrin, Inc.","latestPrice":2.75,"timestamp":1742587200000,"preClose":2.77,"halted":0,"volume":1392082,"hourTrading":{"tag":"盘后","latestPrice":2.8,"preClose":2.75,"latestTime":"17:07 EDT","volume":99973,"amount":274924.393128,"timestamp":1742591265213},"delay":0,"floatShares":72591276,"shares":100702249,"eps":-2.680881,"marketStatus":"Market Closed","change":-0.02,"latestTime":"03-21 16:00:00 EDT","open":2.74,"high":2.84,"low":2.704,"amount":3849662.866759,"amplitude":0.049097,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.680881,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1742803200000},"marketStatusCode":7,"adr":0,"listingDate":1683259200000,"exchange":"NASDAQ","adjPreClose":2.77,"preHourTrading":{"tag":"盘前","latestPrice":2.77,"preClose":2.77,"latestTime":"09:14 EDT","volume":35,"amount":99.669997,"timestamp":1742562844632},"postHourTrading":{"tag":"盘后","latestPrice":2.8,"preClose":2.75,"latestTime":"17:07 EDT","volume":99973,"amount":274924.393128,"timestamp":1742591265213},"volumeRatio":1.868568657974565,"impliedVol":1.3109,"impliedVolPercentile":0.46},"requestUrl":"/m/hq/s/SLRN","defaultTab":"news","newsList":[{"id":"2521494318","title":"ACELYRIN Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2521494318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521494318?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 05:01","pubTimestamp":1742504512,"startTime":"0","endTime":"0","summary":"ACELYRIN Inc reports results for the quarter ended December 31 - Earnings SummaryACELYRIN Inc SLRN.OQ reported a quarterly adjusted loss of 79 cents per share for the quarter ended December 31, higher","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL8N3Q32DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN"],"gpt_icon":0},{"id":"2520140810","title":"Insider Stock Sales Shake Up ACELYRIN, INC.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520140810","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520140810?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 10:06","pubTimestamp":1742436373,"startTime":"0","endTime":"0","summary":"New insider activity at ACELYRIN, INC. ( ($SLRN) ) has taken place on March 20, 2025. Senior Vice President and General Counsel Mina Kim recently s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insider-stock-sales-shake-up-acelyrin-inc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insider-stock-sales-shake-up-acelyrin-inc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLRN","INC"],"gpt_icon":0},{"id":"2520061728","title":"Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2520061728","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520061728?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 16:46","pubTimestamp":1742287581,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Acelyrin, Inc.  stands against other best short-term stocks with a buying opportunity for investors.Thrilling highs, daunting lows, and the energized chase after the next big opportunity – this thoroughly defines the current stock market. In this roller coaster ride, momentum investing is an often-seen strategy piquing the investors’ interest, which involves capitalizing on continuing existing market trends. The approach holds onto the hope that high performers in the past will continue to perform better in the future as well. A curious subset within the strategy is the price momentum stocks, whose recent downturns are seen as an opportunity as they show potential for a swift rebound.READ ALSO:12 Best Multibagger Stocks to Buy in 2025. The pursuit of high returns can be tempting. Hence, investors are suggested to estimate the risk tolerance levels and long-t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acelyrin-inc-slrn-one-best-084621773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MNQmain","QID",".IXIC","SQQQ","SLRN","USJW.SI","QLD","USAW.SI","BK4161","NQmain","NVIW.SI","PSQ","TQQQ","TSYW.SI","CVR"],"gpt_icon":1},{"id":"2519350938","title":"Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2519350938","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519350938?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:15","pubTimestamp":1741868100,"startTime":"0","endTime":"0","summary":"Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company.The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.Acelyrin said Tang Capital held 8.8% of its outstanding common stock.Tang Capital didn't immediately respond to a request for comment issued through LinkedIn.Poison pills, also called shareholder-rights plans, are legal maneuvers that make it hard for shareholders to build their stakes beyond a set point by triggering an option for others to buy more shares at a discount.Acelyrin in February received an unsolicited indication of interest from Concentra Biosciences, a portfolio company under Tang Capital Management, for an acquisition at","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","SLRN","BK4007","BK4139"],"gpt_icon":0},{"id":"2519835974","title":"Acelyrin Adopts Stockholder Rights Plan; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2519835974","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519835974?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:08","pubTimestamp":1741867716,"startTime":"0","endTime":"0","summary":"Acelyrin  said Thursday it has adopted a stockholder rights plan in response to Tang Capital Partners' accumulation of an 8.8% stake in the company.Under the plan, each shareholder will receive one right per common share held as of March 24. The rights will activate if any shareholder acquires 10% or more of the company's common stock. Upon activation, shareholders excluding the acquiring party can buy additional shares at the exercise price, additional shares of common stock having a then-current market value of twice such exercise price, the company said.The rights plan, which also has customary flip-over and exchange features, is effective immediately and set to expire on March 12, 2026Shares were over 3% higher in recent premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLRN","BK4139"],"gpt_icon":0},{"id":"2519288793","title":"ACELYRIN Adopts Limited-Duration Stockholder Rights Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2519288793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519288793?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 19:00","pubTimestamp":1741863601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nTUA7YB0LS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLRN"],"gpt_icon":0},{"id":"2519887248","title":"ACELYRIN Adopts Limited-Duration Stockholder Rights Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887248","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887248?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"LOS ANGELES, March 13, 2025  -- ACELYRIN, INC. , a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan .The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value.The Rights Plan is effective immediately and will expire on March 12, 2026.ACELYRIN stockholders do not need to take any further action at this time.Guggenheim Securities, LLC is serving as financial advisor to ACELYRIN and Fenwick & West LLP and Paul Hastings LLP are serving as its legal counsel.ACELYRIN, INC.  is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commerciali","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acelyrin-adopts-limited-duration-stockholder-110000068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","SLRN","ALMS"],"gpt_icon":0},{"id":"2517489600","title":"Sector Update: Health Care Stocks Lower Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2517489600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517489600?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 03:00","pubTimestamp":1741114825,"startTime":"0","endTime":"0","summary":"Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the Health Care Select Sector SPDR Fund  shedding 0.4%.The iShares Biotechnology ETF  rose less than 0.1%.In corporate news, Walgreens Boots Alliance  is nearing the completion of a go-private deal with Sycamore Partners for around $10 billion, The Wall Street Journal reported late Monday. Walgreens shares jumped 7.3%.UnitedHealth Group  shares rose 2.2% after a retired federal judge in her role as special master issued a recommendation favoring UnitedHealth to the presiding federal judge in a lawsuit brought by the US Department of Justice, which accused the healthcare company of failing to return money it received via the Medicare Advantage program.Acelyrin  and Alumis  reaffirmed Tuesday their commitment to merge in an all-stock deal, as Acelyrin said its board had determined that Concentra Biosciences' unsolicited indication of interest is \"not reasonably expected to result in a superior pr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0310800379.SGD","LU2552382215.SGD","LU0211328371.USD","IE00B19Z3581.USD","SG9999017495.SGD","LU0211326755.USD","LU0234572021.USD","LU2236285917.USD","LU1988902786.USD","LU0823416689.USD","WBA.AU","SLRN","LU0820562030.AUD","LU1267930227.SGD","LU0158827781.USD","LU1506573853.SGD","UNH","LU2347655156.SGD","LU0316494557.USD","LU0557290698.USD","LU1720051017.SGD","WBA","LU1548497426.USD","LU2491050154.USD","LU0417517546.SGD","LU0353189763.USD","LU1267930730.SGD","IBB","LU0672654240.SGD","LU1854103824.USD","LU0683600562.USD","SG9999014898.SGD","LU1291159041.SGD","SG9999014906.USD","SG9999014914.USD","IE00BJJMRX11.SGD","LU1778281490.HKD","LU2361044949.HKD","LU0795875086.SGD","LU0238689110.USD","LU0321505439.SGD","IE00BFSS7M15.SGD","LU0708994859.HKD","LU0661504455.SGD","LU1023059063.AUD","XLV","LU1261432733.SGD","LU1551013342.USD","ALMS","LU2552382058.USD"],"gpt_icon":1},{"id":"2517600360","title":"BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2517600360","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517600360?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 02:46","pubTimestamp":1741114004,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealthEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN1GU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UAL","NEXT","DSP","WBA","YMAB","PEP","EVGO","2NVD.UK","HUT","TNYA","AMLX","CNX","STIM","NVIW.SI","UNH","ATEC","ENPH","JBLU","AGH","NVDY","WVE","FITB","AAL","ILMN","CAPR","NVDS","SLRN","OKTA","WGRX","3NVD.UK","NVDD","MDLZ","SNVD.UK","EQT","PEPG","NVDU","ULCC"],"gpt_icon":1},{"id":"2517606576","title":"ACELYRIN Shares Down 6.5% After Co Reiterates Merger With Alumis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517606576","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517606576?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 00:14","pubTimestamp":1741104870,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN1OG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLRN"],"gpt_icon":0},{"id":"2516608325","title":"Acelyrin Reaffirms Merger Deal With Alumis","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608325","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516608325?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 23:10","pubTimestamp":1741101018,"startTime":"0","endTime":"0","summary":"Acelyrin (SLRN) and Alumis (ALMS) reaffirmed Tuesday their commitment to merge in an all-stock transaction, as Acelyrin said its board had determined that Concentra Biosciences' unsolicited indication","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS","BK4007","BK4139","SLRN"],"gpt_icon":0},{"id":"2516067205","title":"REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2516067205","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516067205?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:44","pubTimestamp":1741099479,"startTime":"0","endTime":"0","summary":"REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offerCorrects company name to \"Concentra\" in bullet 3, corrects typographical error in bullet 5** Shares of dru","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN1F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CON","SEM","SLRN","ALMS"],"gpt_icon":0},{"id":"2516867254","title":"Acelyrin says Concentra indication not expected to result in superior proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516867254","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516867254?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:12","pubTimestamp":1741097544,"startTime":"0","endTime":"0","summary":"ACELYRIN (SLRN) announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acelyrin-says-concentra-indication-not-expected-to-result-in-superior-proposal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acelyrin-says-concentra-indication-not-expected-to-result-in-superior-proposal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLRN","BK4139"],"gpt_icon":0},{"id":"2516383674","title":"BRIEF-Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516383674","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516383674?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:07","pubTimestamp":1741097248,"startTime":"0","endTime":"0","summary":"BRIEF-Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis MergerMarch 4 (Reuters) - Alumis Inc ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA475HLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN","BK4139","ALMS","BK4007"],"gpt_icon":0},{"id":"2516674655","title":"Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674655","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674655?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:06","pubTimestamp":1741097208,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) and ACELYRIN (SLRN) reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biop...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acelyrin-alumis-reaffirm-strategic-financial-rationale-of-proposed-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acelyrin-alumis-reaffirm-strategic-financial-rationale-of-proposed-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","BK4139","BK4007","SLRN"],"gpt_icon":0},{"id":"2516748486","title":"BRIEF-Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516748486","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516748486?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:06","pubTimestamp":1741097191,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed MergerMarch 4 (Reuters) - Alumis Inc ALMS.O:ALUMIS AND ACELYRIN REAFFIRM STRATEGIC AND FINANCIAL RATIONALE OF PROPOSED ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA48S77V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS","SLRN","BK4139"],"gpt_icon":0},{"id":"2516783671","title":"ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516783671","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516783671?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:01","pubTimestamp":1741096860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA149XQ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","ALMS","SLRN"],"gpt_icon":0},{"id":"2516751671","title":"Press Release: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516751671","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516751671?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:01","pubTimestamp":1741096860,"startTime":"0","endTime":"0","summary":"Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet. LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025  -- ACELYRIN, INC.  and Alumis Inc.  today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases.\"The ACELYRIN Board of Directors is confident that the all-stock transaction with Alumis maximizes long-term value for ACELYRIN stockholders and continues to recommend that stockholders support the planned merger,\" said Mina Kim, Chief Executive Officer of ACELYRIN. \"We chose to enter into the merger agreement with Alumis after a comprehensive assessment of strategic alternatives, and believe this is the best outcome for ACELYRIN stockholders. We're excited about the combined company's potential for significant value creation as a result of its expanded portfolio, strong financial foundation and proven leadership.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLRN","BK4007","ALMS"],"gpt_icon":0},{"id":"2516671164","title":"ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516671164","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516671164?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA475HLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLRN","ALMS","BK4007","BK4139"],"gpt_icon":0},{"id":"2516867175","title":"Press Release: ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516867175","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516867175?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":"ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger. All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders. LOS ANGELES, March 04, 2025  -- ACELYRIN, INC. , a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors determined that the unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, is not reasonably expected to result in a superior proposal to the planned merger with Alumis Inc. .The ACELYRIN Board of Directors is confident that the all-stock transaction with Alumis maximizes long-term value for ACELYRIN stockholders and continues to recommend that ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN","BK4139","ALMS","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acelyrin.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.2791},{"period":"3month","weight":-0.127},{"period":"6month","weight":-0.4898},{"period":"1year","weight":-0.6465},{"period":"ytd","weight":-0.1242}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0799},{"period":"3month","weight":-0.046},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.08},{"period":"ytd","weight":-0.0377}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.","exchange":"NASDAQ","name":"Acelyrin, Inc.","nameEN":"Acelyrin, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acelyrin, Inc.(SLRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Acelyrin, Inc.(SLRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Acelyrin, Inc.,SLRN,Acelyrin, Inc.股票,Acelyrin, Inc.股票老虎,Acelyrin, Inc.股票老虎国际,Acelyrin, Inc.行情,Acelyrin, Inc.股票行情,Acelyrin, Inc.股价,Acelyrin, Inc.股市,Acelyrin, Inc.股票价格,Acelyrin, Inc.股票交易,Acelyrin, Inc.股票购买,Acelyrin, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acelyrin, Inc.(SLRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Acelyrin, Inc.(SLRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction